方盛制药：子公司紫英颗粒临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its self-developed traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [1] Group 1 - The approved clinical trial is specifically for Ziying Granules, which targets chronic pelvic pain associated with pelvic inflammatory disease sequelae [1] - Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine and has not yet been launched in domestic or international markets [1] - The symptoms addressed by Ziying Granules include lower abdominal pain, lumbar discomfort, increased vaginal discharge, and other related symptoms [1]